Dyne Therapeutics ( NASDAQ: DYN ) has priced its underwritten public offering of 10.5M shares at $31 per share. Gross proceeds to Dyne ( DYN ) from the offering are expected to be $325.
5M. Underwriters have been granted a 30-day option to buy up to an additional ~1.6M shares at the public offering price.
The offering is expected to close on or about May 24. More on Dyne Therapeutics Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials Dyne announces data from early stage trials of muscular dystrophy treatments Dyne Therapeutics appoints John Cox CEO.
